Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleCancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE